Everything below concerns thymosin alpha 1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-12. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
== South America == In June 2026, three Brazilian sisters with a combined age of 313, were recognized by Guinness as the oldest living trio of siblings in the world. The sisters, 103, 104 and 106 years old live, in Rio de Janeiro. They were discovered through a global organization that verifies longevity records, called LongeviQuest. Researchers are interested in not only the environmental, but also the genetic components that contribute to longevity. Ben Meyers, the CEO of LongeviQuest stated "When sisters reach that age, there is clearly a strong genetic component. But because they live near each other, they also have a support network, with family able to help when needed. There is definitely a community aspect as well."
Among these, the recently described (2023) fungus Tremella parietinae is found exclusively on X. parietina, where it induces the formation of convex, orange to yellow galls within the hymenium of its apothecia. This fungus is known from several European countries—including Austria, Spain, and Sweden—and likely has a broader distribution wherever its host occurs. Another lichenicolous fungus, Tremella occultixanthoriae, parasitizes X. parietina but develops on the lower surface of the thallus and produces four-celled basidia. Both fungi belong to a broader complex of Tremella species that specialize in infecting Teloschistaceae lichens, often with strict host specificity. Some common saprotrophic fungi not typically associated with lichens have also been found colonizing X. parietina. These include Epicoccum nigrum, appearing as dark purple-brown hemispherical heaps on the surface of apothecial discs, and Periconia digitata, which forms distinctive stalked spherical heads resembling tiny pins on the apothecia and thallus. The environmental conditions that trigger such extensive fungal colonization remain unclear, although factors like prolonged snow cover, high rainfall, or other environmental stressors may initially weaken the lichen, making it susceptible to fungal invasion. Another lichenicolous fungus is Arthonia parietinaria, which was long misidentified as Arthonia molendoi or A. epiphyscia. This species forms mat black, dull ascomata that are arranged in large groups of up to 20–30 (sometimes 50) on the thallus surface of X.
14 April – Trixie Gardner, Baroness Gardner of Parkes, 96, British politician, member of the House of Lords since 1981 20 April – Doreen Massey, Baroness Massey of Darwen, 85, British politician, member of the House of Lords (since 1999). 23 April – Frank Field, Baron Field of Birkenhead, 81, British politician, MP (1979–2019) and member of the House of Lords (since 2020). David Marquand, 89, British politician and academic administrator, MP (1966–1977) and principal of Mansfield College, Oxford (1996–2002). 29 April – Andrew Stunell, Baron Stunell, 81, British politician, MP (1997–2015) and member of the House of Lords (since 2015). 10 May – Colin Breed, 76, British politician, MP (1997–2010). (death announced on this date) 12 May – Michael Brudenell-Bruce, 8th Marquess of Ailesbury, 98, British hereditary peer, army officer and stockbroker, member of the House of Lords (1974–1999). 24 May – Stuart Borrowman, 71, Scottish politician. 5 June – Charles Allsopp, 6th Baron Hindlip, 83, British peer and businessman, member of the House of Lords (1993–1999). 26 June – Richard Taylor, 89, British politician, MP (2001–2010). 29 July – Robert Fellowes, Baron Fellowes, 82, British courtier, private secretary to the sovereign (1990–1999) and member of the House of Lords (1999–2022). Peter Reddaway, 84, British-American political scientist. 4 August – Anthony Hamilton-Smith, 3rd Baron Colwyn, 82, British dentist and peer, member of the House of Lords (1967–2022). 22 August – Delwyn Williams, 85, British politician and solicitor, MP (1979–1983).
Sources: en.wikipedia.org
== The mechanism of thiol–disulfide exchange between oxidoreductases == The mechanism of thiol–disulfide exchange between oxidoreductases is understood to begin with the nucleophilic attack on the sulfur atoms of a disulfide bond in the oxidised partner, by a thiolate anion derived from a reactive cysteine in a reduced partner. This generates mixed disulfide intermediates, and is followed by a second, this time intramolecular, nucleophilic attack by the remaining thiolate anion in the formerly reduced partner, to liberate both oxidoreductases. The balance of evidence discussed thus far supports a model in which oxidising equivalents are sequentially transferred from Ero1 via a thiol–disulfide exchange reaction to PDI, with PDI then undergoing a thiol–disulfide exchange with the nascent polypeptide, thereby enabling the formation of disulfide bonds within the nascent polypeptide.
== Successors == A trailer for a sequel, Frontline Force II: Defiance, was released in January 2003. In December 2004, Frontline Force 2.0 was cancelled and development was moved to Source engine. The unfinished version of 2.0 was still released on the official website. In April 2005, the new mod was revealed as Front Line Force: Classic. A more tactical version of Frontline Force, titled Frontline: Tactics, was in development as a Half-Life mod in 2001. By 2007 its development was moved to Source engine under the title Frontline Force: Tactics.
== History == The company was founded by Jerry Cole and John Parmer in 1955 and took up shop in a 1,200-square-foot (110 m2) loft on West Illinois Street in downtown Chicago. In the 1960s, Cole-Parmer acquired Masterflex peristaltic pumps, followed shortly by the purchases of Gilmont Instruments and Manostat Pumps. They were acquired by Fisher Scientific, now Thermo-Fisher Scientific, in 2001. On July 17, 2014, Thermo Fisher Scientific Inc. agreed to sell one of its lab units, Cole-Parmer, to private-equity firm GTCR for $480 million in cash. The company has previously said its $13.6 billion acquisition of Life Technologies Corp. would allow it to cut costs while gaining from next-generation genetic-sequencing machines. It has also sought to expand in Asia-Pacific markets. In 2025, Cole-Parmer was sold to Brookfield Asset Management Ltd.'s private equity group and Caisse de dépôt et placement du Québec for a reported 1.4 billion dollars (USD).
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.